ArticleGastroenterology and hepatology from bed to bench2024
Somatostatin analogs in the treatment of gastrointestinal angiodysplasia bleeding: a systematic review.
Article in Gastroenterology and hepatology from bed to bench, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sirolimus and gastrointestinal angiodysplasia: Can an established agent change the way gastrointestinal bleeding is managed?World journal of gastroenterology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: We aimed to perform a systematic review to gather evidence on the efficacy of somatostatin analogs (SA) in managing bleeding gastrointestinal angiodysplasias (GIADs). Background: Some usual treatment modalities for bleeding caused by GIADs include endoscopic or surgical management. However, considering their availability and side effects, they may not be feasible for every patient. On that account, pharmacological management may become a safe and effective option. Methods: In January 2024, a systematic review of the literature was conducted using the PubMed/Medline, Cochrane Library, and Scopus databases. The Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) framework was followed. Inclusion in this review was restricted to randomized clinical trials (RCTs) or observational studies comparing the use of SA as the main or complementary therapy in patients with GIADs. The outcomes of interest were hemoglobin levels, transfusion requirements, bleeding, and safety/adverse effects. Results: Seven studies were included in the systematic review, two RCTs and five observational studies. There were 682 patients, of which 166 (24.3%) received any form of treatment involving SA. The studies varied greatly regarding follow-up, SA of choice, and other treatments associated with SA or as a control. Lanreotide appears to be able to significantly improve hemoglobin levels when associated with various treatments, whereas octreotide does not. One RCT found a significant reduction in blood or iron transfusion units when comparing SA to a standard of care, but other studies had mixed results. Lanreotide may be useful in reducing bleeding episodes in patients treated with argon plasma coagulation with double-balloon enteroscopy. Gastrointestinal adverse events such as diarrhea, vomiting, and abdominal pain were commonly reported across studies. Conclusion: The majority but not all included studies suggest that SA may improve hemoglobin levels and reduce bleeding in patients with GIAD. However, the studies included small sample sizes and were not of strong statistical power. Further RCTs with larger populations are necessary to validate the effectiveness of SA in managing patients with GIAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.